KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2025)

Historic Operating Leases for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Q3 2025 value amounting to $42.2 million.

  • Supernus Pharmaceuticals' Operating Leases rose 1063.87% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 1063.87%. This contributed to the annual value of $34.3 million for FY2024, which is 1747.3% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Operating Leases stood at $42.2 million for Q3 2025, which was up 1063.87% from $31.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Operating Leases high stood at $56.0 million for Q1 2021, and its period low was $31.8 million during Q2 2025.
  • In the last 5 years, Supernus Pharmaceuticals' Operating Leases had a median value of $42.2 million in 2025 and averaged $41.9 million.
  • In the last 5 years, Supernus Pharmaceuticals' Operating Leases soared by 6331.0% in 2021 and then plummeted by 2331.52% in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Operating Leases stood at $47.8 million in 2021, then dropped by 10.44% to $42.8 million in 2022, then fell by 2.95% to $41.5 million in 2023, then fell by 17.47% to $34.3 million in 2024, then grew by 23.17% to $42.2 million in 2025.
  • Its last three reported values are $42.2 million in Q3 2025, $31.8 million for Q2 2025, and $32.3 million during Q1 2025.